Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00332384 | Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | PHASE3 | COMPLETED | 573 | — | — | Jan 1, 2000 | Nov 1, 2001 | May 30, 2011 | 1 | United States |
| NCT00332436 | Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | PHASE3 | COMPLETED | 586 | — | — | Dec 1, 1999 | Nov 1, 2001 | May 30, 2011 | 1 | United States |
| NCT00332345 | Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | PHASE2 | COMPLETED | 73 | — | — | Jul 1, 1999 | Aug 1, 1999 | May 30, 2011 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| brimonidine/timolol fixed combination | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes * Patient requires IOP-lowering drug in both eyes Exclusion Criteria: * Uncontrolled medical conditions * contraindication to beta-adrenoceptor antagonist or brimonidine therapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Bimatoprost, AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01% |
| Glaukos Corp | GKOS | 1 | — | Travoprost |